Brokers Issue Forecasts for AUTL FY2028 Earnings

Autolus Therapeutics plc (NASDAQ:AUTL) – Equities research analysts at William Blair issued their FY2028 earnings per share estimates for Autolus Therapeutics in a research note issued on Thursday, March 20th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($0.18) for the year. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share.

AUTL has been the subject of several other research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Wells Fargo & Company dropped their price target on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday, March 21st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Autolus Therapeutics currently has a consensus rating of “Buy” and an average price target of $9.52.

Autolus Therapeutics Stock Down 5.3 %

Shares of NASDAQ AUTL opened at $1.62 on Monday. The firm has a 50-day simple moving average of $2.00 and a 200-day simple moving average of $2.87. The stock has a market capitalization of $431.07 million, a price-to-earnings ratio of -1.34 and a beta of 2.07. Autolus Therapeutics has a 52 week low of $1.56 and a 52 week high of $6.48.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $2.98 million.

Hedge Funds Weigh In On Autolus Therapeutics

A number of institutional investors have recently bought and sold shares of AUTL. Wellington Management Group LLP increased its holdings in shares of Autolus Therapeutics by 4.6% during the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock worth $59,562,000 after buying an additional 1,125,454 shares during the last quarter. FMR LLC raised its position in Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after purchasing an additional 5,478,706 shares during the period. TFG Asset Management GP Ltd lifted its stake in shares of Autolus Therapeutics by 3.1% in the 4th quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company’s stock valued at $19,388,000 after purchasing an additional 250,000 shares during the last quarter. Candriam S.C.A. purchased a new position in shares of Autolus Therapeutics during the 4th quarter worth $7,500,000. Finally, AXA S.A. acquired a new stake in shares of Autolus Therapeutics during the 4th quarter worth about $4,288,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.